Nutritional support to prevent and/or mitigate bone marrow toxicity from a cancerous tumor

Patent metadata

Field	Value
Publication number	US-9827216-B2
Application number	US-200913063589-A
Country	US
Kind code	B2
Filing date	Sep 11, 2009
Priority date	Sep 19, 2008
Publication date	Nov 28, 2017
Grant date	Nov 28, 2017

Abstract

The present invention relates to methods and immunonutritional compositions for preventing or mitigating paralysis of the bone marrow, caused by a tumor or neoplasm, between cycles of and after anti-cancer therapy, thereby attaining a better efficacy of the treatment. More particularly, the present invention relates to methods and immunonutritional compositions that can transiently preventing or moderating, bone marrow paralysis or neutropenia of a subject tumor-induced apoptosis or necrosis or other cell damage such that the innate and adaptive immune functions and normal physiology of the bone marrow are preserved, at least in part, which, in turn, lead to (i) a better tolerance and increased efficacy to treatment; (ii) transient augmentation or enhancement of immunocompetence of the immune cell; and (iii) optimization of the effects of and increase of immunocompetence of the immune cell weakened due to paralysis of the bone marrow, caused by a tumor or neoplasm.

First claim

What is claimed is:

1. A method of attenuating chemotherapy-induced neutropenia, the method comprising:
administering enterally an immunonutritional composition to a subject having chemotherapy-induced neutropenia, the subject is undergoing an anti-cancer therapy that comprises an aggressive treatment selected from the group consisting of surgery that removes all or part of a tumor, hormonal treatment that induces apoptosis, radiotherapeutic treatment that induces apoptosis, chemotherapeutic treatment that induces apoptosis, and combinations thereof, and the anti-cancer therapy further comprises neoadjuvant chemotherapeutic treatment before the aggressive treatment, and the composition is administered daily to the subject for a time period extending from a first date between ten and three days before the neoadjuvant chemotherapeutic treatment to a second date between ten and seven days after the aggressive treatment,
wherein the composition comprises immuno-enhancing agents comprising L-arginine, omega-3 fatty acids, and nucleotides.

2. The method of claim 1 , wherein the aggressive treatment is surgery that removes all or part of a tumor.

3. The method of claim 1 , wherein the aggressive treatment is hormonal treatment that induces apoptosis.

4. The method of claim 1 , wherein the aggressive treatment is radiotherapeutic treatment that induces apoptosis.

5. The method of claim 1 , wherein the aggressive treatment is chemotherapeutic treatment that induces apoptosis.

6. The method of claim 1 , wherein the immunonutritional composition is a tube feed.

7. The method of claim 1 , wherein the immunonutritional composition is gel.

8. The method of claim 1 , wherein the immunonutritional composition is a complete nutritional.

9. The method of claim 1 , wherein the composition comprises an additional immunoenhancing agent selected from the group consisting of a probiotic, a probiotic biomass, non-replicating organisms, potassium, uric acid, a single-stranded oligonucleotide, a pathogen/microbial associated molecular pattern (PAMP/MAMP), an active hexose correlated compound, carotenoids, a vitamin D receptor, branched-chain amino acids, theanine, vitamin E, lactoferrin protein, and combinations thereof.

10. The method of claim 1 , wherein the composition comprises a protein source selected from the group consisting of whey protein; casein protein; soy protein; hydrolysates of whey, casein, or soy protein; and combinations thereof.

Assignees

• Schiffrin Eduardo
• Miller Kevin Burke
• Brassart Dominique
• Lantz Olivier Jacques
• Amigorena Sebastian Diego
• Nestec Sa
• Inst Curie

Inventors

• Schiffrin Eduardo
• Miller Kevin Burke
• Brassart Dominique
• Lantz Olivier Jacques
• Amigorena Sebastian Diego

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P37/02

  Immunomodulators · CPC title